Compare Amgen, Inc. (AMGN) vs Amplify Transformational Data Sharing ETF (BLOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Amplify Transformational Data Sharing ETF — how do they compare? Amgen, Inc. trades at $416.98 (market cap $224.14B), while Amplify Transformational Data Sharing ETF trades at $59.55. The key difference: Amgen, Inc. pays a 2.43% dividend while Amplify Transformational Data Sharing ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | BLOK | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | — |
52-Week High | $417.20 | $74.10 |
52-Week Low | $271.18 | $47.36 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
BLOK trades at $60.00, up 1.56% today, but faces bearish technical signals with 14 sell indicators versus 2 buy signals. The stock shows neutral momentum oscillators while moving averages signal downward pressure. Recent institutional activity shows Dynamic Advisor Solutions reduced its position by 81.1% in Q2 2026. The ETF focuses on transformational data sharing companies with exposure to AI infrastructure and blockchain economy participants.
The outlook remains cautious given bearish technical indicators and institutional selling. Investment opportunity exists in the ETF's diversified exposure to data sharing and AI infrastructure growth, but risks include sector volatility and competitive ETF pressure. The dividend of $0.08 scheduled for June 2026 provides minor income support amid uncertain market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →
